Radiopharm Theranostics (ASX: RAD) appoints highly experienced VP-Medical and Corporate Affairs

July 25, 2023 09:30 AM AEST | By Sonal Goyal

Radiopharm Theranostics (ASX: RAD) appoints highly experienced VP-Medical and Corporate Affairs — Image source: Company website

Recent News

Gold Shines Again as Trade Tensions Ease and Fed Concerns Recede

Google Faces UK Legal Challenge Amid Global Scrutiny on Market Dominan...

Copper Momentum Boosts Capstone Shares Amid Trade Optimism

Mexico's sole antimony smelter is resuming operations, positioning EV...

Highlights

Radiopharm has announced the appointment of Dr Sherin Al-Safad as Vice President Medical and Corporate Affairs.

She held leadership roles at multinational biotechnology and pharmaceutical companies.

RAD shares gained over 4.5% in the morning hours.

Australian radiopharmaceutical products developer Radiopharm Theranostics Limited (ASX:RAD) has appointed Dr Sherin Al-Safad as Vice President Medical and Corporate Affairs, effective 24 July 2023. Dr Al-Safadi carries extensive experience in the pharmaceuticals and biotechnology space.

Dr Al-Safadi has a doctorate degree in neurobiology from Concordia University. She is a MSc in Pharmacology from McGill University and an MBA from the John Molson School of Business in Entrepreneurship & Management.

Rich industry experience

The most recent role of Dr Al-Safadi was Vice-President – Medical Affairs at POINT Biopharma, where she assembled and led a medical affairs division. At POINT, she led the strategic planning for Phase III support and launch preparation of radiopharmaceuticals. She also offered leadership and strategic input for business development and licencing opportunities.

Currently, she is serving at Foundation Amal (Canada-USA) as co-founder and president and managing an executive leadership team (12 directors and members). She has overseen the firm’s successful 2021 cross-border expansion into the United States and led the development of branding and communication strategy.

Previously, she was Director of Global Medical Affairs Oncology at Bayer. During her time there, she led franchise-specific strategic guidance and Key Performance indicators for Med affairs teams launch excellence. It incorporated the transition to hybrid digital engagement.

RAD shares traded at AU$0.110 on 24 July 2023.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.